Filing Details
MoonLake Immunotherapeutics (NASDAQ:MLTX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 10, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:MLTX
MoonLake Immunotherapeutics (MLTX) Files Quarterly Report for Q0
MoonLake Immunotherapeutics (NASDAQ:MLTX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 10, 2026.
At publication ·
What changed
MoonLake Immunotherapeutics (NASDAQ:MLTX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- MoonLake Immunotherapeutics filed its Q0 2026 quarterly report (Form 10-Q) on August 10, 2026 with the SEC.
- The company's stock trades at $17.33 with a market capitalization of $895.6 million.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance, including updated risk factors and emerging trends since the last filing.
Market Context
MoonLake Immunotherapeutics's stock currently trades at $17.33 with a market capitalization of $895.6M.
The 10-Q provides MoonLake Immunotherapeutics's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for MoonLake Immunotherapeutics are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MLTX Stock Page
Frequently Asked Questions
Where can I read MLTX's SEC filings?
Browse all filings on our MLTX SEC filings page.
What types of SEC filings does MoonLake Immunotherapeutics file?
Public companies like MoonLake Immunotherapeutics file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.